Recurrent or Progressive Astrocytoma – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Recurrent or Progressive Astrocytoma Emerging Therapy and TPP Insights

Thelansis’s “Recurrent or Progressive Astrocytoma Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Recurrent or Progressive Astrocytoma Overview

Recurrent or progressive astrocytoma is a brain tumour that grows or returns after treatment; management depends on molecular subtype and CNS WHO grade. Adult diffuse astrocytomas are commonly IDH-mutant (grades 2–4); many IDH-wildtype high-grade diffuse tumours are classified separately as glioblastoma. Symptoms include seizures, headaches, cognitive changes and focal neurological deficits. MRI progression must be distinguished from treatment-related effects. Management may include repeat resection, selected re-irradiation, alkylating chemotherapy or a clinical trial, guided by prior therapy, tumour location and functional status. Vorasidenib is FDA-approved for IDH-mutant grade 2 astrocytoma after surgery, not as a general treatment for recurrent high-grade disease. IDH-directed combinations and peptide vaccines are being studied in selected recurrent IDH-mutant tumours; benefit remains unproven. Preserving neurological function while controlling tumour growth remains a major unmet need.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
• Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)